4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine
| Status: | Withdrawn |
|---|---|
| Conditions: | Migraine Headaches |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/10/2019 |
| Start Date: | January 2019 |
| End Date: | January 2024 |
Prospective, Randomized, Placebo-controlled, Phase 2 Study of 4-aminopyridine, Atenolol, or Placebo in the Treatment of Patients With Vestibular Migraine
This phase 2 randomized study will be used to test the efficacy of 4-aminopyridine (4AP) or
atenolol to reduce severity and frequency of vestibular and headache symptoms of vestibular
migriane sufferers. Blinded study drug will be taken by mouth twice a day for 14 weeks on
study.
atenolol to reduce severity and frequency of vestibular and headache symptoms of vestibular
migriane sufferers. Blinded study drug will be taken by mouth twice a day for 14 weeks on
study.
Inclusion Criteria:
- Severe vestibular migraine (VM)
Exclusion Criteria:
- Neurologic or otologic disease other than VM
- Psychiatric illness requiring medication
- Medical illness including cancer, coronary artery or cerebrovascular disease
- Known allergy to one of the test medications
- Contraindication to use of one of the test medications - asthma, symptomatic
hypotension, history of seizures
- Taking migraine prophylactic medication or vestibular suppressants.
- Pregnant or breast feeding women
We found this trial at
1
site
243 Charles St
Boston, Massachusetts 02114
Boston, Massachusetts 02114
(617) 523-7900
Phone: 617-573-4192
Massachusetts Eye & Ear Infirmary Whether you see our physicians at Mass. Eye and Ear's...
Click here to add this to my saved trials
